Glepaglutide
Investigational — GLP-2 analog (glepaglutide) — not approved.
What it's for
Investigational — GLP-2 analog (glepaglutide) — not approved.
What it's for
Glepaglutide is an still being studied GLP-2 medicine that turns a receptor signal on designed for less frequent dosing in SBS.
What it does for the body
Studied to reduce parenteral support needs in short bowel syndrome. Not approved. In plain terms: researchers may study it, but that does not make it an approved everyday medicine in the U.S.
What it targets
GLP-2 pathway lining of the gut growth and absorption enhancement. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Glepaglutide is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Glepaglutide — FDA.gov search
- ClinicalTrials.gov search: Glepaglutide — U.S. clinical trials registry
- Drugs@FDA search: Glepaglutide — FDA drug database (if approved)
- PubMed search: Glepaglutide — NCBI PubMed
- PubMed Central search: Glepaglutide — NCBI PMC